Related Experiment Videos
Comparative analysis of normal and malignant CD5+ B lymphocytes.
1Dipartimento di Scienze Biomediche e Oncologia Umana, Università di Torino, Italy.
Nouvelle Revue Francaise D'Hematologie
|January 1, 1988
Summary
Normal CD5+ B lymphocytes, considered the counterpart to B-cell chronic lymphocytic leukemia (B-CLL), were analyzed for phenotype, cell cycle, and cytoskeleton. This study compares these normal B cells with malignant CD5+ cells from B-CLL patients.
Area of Science:
- Immunology
- Cell Biology
- Hematology
Background:
- The CD5 molecule is expressed on a major B cell population in fetal development and cord blood, decreasing significantly in adults.
- CD5 is also a marker for malignant B cells in B-cell chronic lymphocytic leukemia (B-CLL).
- CD5+ B cells are considered the normal counterpart to B-CLL, despite no direct proof of transformation targeting.
Purpose of the Study:
- To analyze the phenotype of normal CD5+ B lymphocytes.
- To compare cell cycle control and cytoskeleton organization between normal CD5+ B cells and malignant CD5+ B-CLL cells.
Main Methods:
- Phenotypic analysis of B lymphocytes.
- Assessment of cell cycle control mechanisms.
- Investigation of cytoskeleton organization.
Main Results:
- Detailed characterization of normal CD5+ B cell phenotype.
- Comparative analysis of cell cycle regulation in normal vs. malignant B cells.
- Evaluation of differences in cytoskeleton organization.
Conclusions:
- Provides a comparative dataset for normal CD5+ B cells and B-CLL cells.
- Highlights potential differences in cell cycle and cytoskeleton relevant to B-CLL pathogenesis.
- Establishes a baseline for understanding the normal CD5+ B cell counterpart.